Edition:
Deutschland

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,052.00GBp
24 Nov 2017
Change (% chg)

-22.00 (-2.05%)
Prev Close
1,074.00
Open
1,078.00
Day's High
1,079.00
Day's Low
1,050.00
Volume
968,376
Avg. Vol
985,816
52-wk High
2,346.00
52-wk Low
906.50

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Buy/Sell

Sell Hold Buy
2.64 Mean rating from 14 analysts

Overall

Beta: 1.34
Market Cap(Mil.): £2,897.33
Shares Outstanding(Mil.): 240.65
Dividend: 8.50
Yield (%): --

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

UPDATE 2-European shares suffer worst day since June as earnings underwhelm

* ECB supervisor lifts Italian banks, results help Commerzbank

Photo

Falls in Burberry, housebuilders pile pressure on FTSE

LONDON Heavy losses from luxury group Burberry weighed on Britain's top share index on Thursday which hit a two-week low as investors showed anxiety about the retail and housebuilding sectors.

UPDATE 1-Falls in Burberry, housebuilders pile pressure on FTSE

* Mid-cap Hikma's trading update disappoints (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)

Britain's FTSE under pressure as Burberry revamps its strategy

LONDON, Nov 9 A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus.

European shares open a touch lower as more Q3 earnings pour in

LONDON, Nov 9 European shares opened in negative territory on Thursday, as a flurry of corporate earnings for the third quarter triggered sharp prices moves across some sectors and bourses.

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Nov 9 Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

UPDATE 1-UK Stocks-Factors to watch on Nov 9

Nov 9 Britain's FTSE 100 index futures are seen opening down 0.1 percent ahead of the cash market open.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.46%
Rohstoffe +0.04%
Industrie +0.19%
Konjunktur abhängige Waren & Dienstleistungen +0.10%
Konjunktur unabhängige Waren & Dienstleistungen +0.09%
Finanzindustrie +0.19%
Pharma +0.49%
Technologie +0.31%
Telekommunikation +0.10%